Comparison of Fluconazole and Clotrimazole in the Treatment of Acute Candida Albicans Vulvovaginitis
AbstractObjective: This study compared two antifungal drugs, fluconazole and clotrimazole for the treatment of vulvo vaginal candidiasis. Materials and Methods: This randomized clinical trial was conducted on 120 women with vulvo vaginal candidiasis during a six month period. All patients answered a standard questionnaire containing questions about symptoms of vulvovaginal candidiasis and presence of vaginal discharge and signs of vulvar and vaginal inflammation were documented according to physical examination. Two swabs of vaginal discharge were obtained for each woman, one for direct smear, another for culture. The culture medium was Sabouraud Dextrose Agar (SDA). Patients were randomized into two groups of clotrimazole (vaginal cream for 7 days and 150 mg fluconazole in a single dose. Clinical and paraclinical responses were calculated.Results: Clinical improvement occurred in 96 cases (80%). This value was 86.7% and 73.3%for clotrimazole and fluconazole, respectively (P-value=0.04). Paraclinical response on tenth day of treatment was observed in 87 patients (72.5%). This value was 66.7% and 78.3%for clotrimazole and fluconazole groups, respectively (P-value=0.110). Mean days of treatment was 4.06 ±1.30 days for clotrimazole and 2.70 ±0.78 days for fluconazole (p value =0.031).Conclusion: Most of the clinical and paraclinical responses to the drugs used for the treatment of vulvo vaginal candidiasis are in the favour of fluconazole.
Fidel PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996 ; 9: 335–48.
Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995; 172: 1263-8.
Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole- resistant Candida albicans in a female who was not infected with human immuno-deficiency virus. Clin Infect Dis 1996; 22: 726-7.
Sobel JD, Chaim W. Therapy of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997; 24: 649-52.
Dorrell L, Edwards A .Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles. Sex Transm Infect 2002; 78: 308-9.
Buscemi L, Arechavala A, Negroni R. Study of acute vulvovaginitis in sexually active adult women, with special reference to candidiasis, in patients of the Francisco J Muñiz Infectious Diseases Hospital. Rev Iberoam Micology 2004; 21: 177-81.
Cross EW, Park S , Perlin DS. Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist 2000; 6: 155-61.
Elliott KA. Managing patients with vulvovaginal candidiasis. Nurse Pract 1998; 23: 44-6, 49-53.
Nyirjesy P, Seeney SM, Grody MH, Jordan CA, Buckley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995; 173: 820-23.
Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G . Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997; 176: 138-41.
Galbán B, Mariscal F. Epidemiology of candidemia in ICU. Rev Iberoam Micol 2006; 23: 5-12.
Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol 1991; 165: 1168-76.
Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569-74.
Abu-Elteen KH, Abdul Malek AM, Abdul Wahid NA. Prevalence and susceptibility of vaginal yeast isolates in Jordan. Mycoses 1997; 40: 179-85.
Kariman NS, Shafaei Z, Afrakhteh M, Valaei N, Ahmadi M. Comparing Fluconazole and Clotrimazole in treatment of Candida Albicans vaginitis. Behbood 2002;14:9-16.
Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T. Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. Chemotherapy 1998; 44: 364-8.
O-Praserts P, Bourlert A. Comparative study of fluconazole and clotrimazole for the treatment of Vulvovaginal Candidiasis. Sex Transm Dis 1995; 22: 228-30.
Vacheva-Dobrevski R, Kovachev S, Nacheva A, Stoev S, Vasilev N. Comparative study of Itraconazole and Fluconazole therapy in vaginal candidiasis. Akush Ginekol (Sofiia) 2004; 43: 20-3.
Richter SS, Galask R P, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155–62.
Houang ET, Chappatte O, Byrne D, Macrae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990; 34: 909-10.
Saporiti AM, Gómez D, Levalle S, Galeano M, Davel G, Vivot W,et al. Vaginal candidiasis: Etiology and sensitivity profile to antifungal agents in clinical use Rev Argent Microbiol 2001; 33: 217-22.
Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, et al. Fluconazole Susceptibility of Vaginal Isolates Obtained from Women with Complicated Candida Vaginitis: Clinical Implications. Antimicrob Agents chemother 2003; 47: 34–8.
Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemio-logic, diagnostic and therapeutic consideration. Am J Obstet Gynecol 1998; 178: 203-11.
Li J, Fan SR, Liu XP, Li DM, Nie ZH, Li F, et al. Biased genotype distributions of candida albicans strains associated with vulvovaginal candidiasis and candidal balanoposthitis in china. Clin Infect Dis 2008; 47: 1119–25.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.